Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?-Reference-Cited by-同舟云学术

Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?

Published:2012-02 Issue:2 Volume:61 Page:307-316
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Sonpavde Guru,Choueiri Toni K.,Escudier Bernard,Ficarra Vincenzo,Hutson Thomas E.,Mulders Peter F.,Patard Jean-Jacques,Rini Brian I.,Staehler Michael,Sternberg Cora N.,Stief Christian G.

Publisher

Elsevier BV

Subject

Urology

Reference59 articles.

1. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma;McDermott;J Clin Oncol,2005

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

4. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206;Rini;J Clin Oncol,2008

5. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival;Escudier;J Clin Oncol,2010

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological characterization and clinical value of PLOD gene family in clear cell renal cell carcinoma;2024-04-09

2. Decreased expression of TXNIP is associated with poor prognosis and immune infiltration in kidney renal clear cell carcinoma;Oncology Letters;2024-01-12

3. The emerging role of LncRNA AWPPH in multiple cancers: a review study;Current Molecular Medicine;2023-08-16

4. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma;Frontiers in Genetics;2022-12-01

5. Two novel lncRNAs AF111167.2 and AL162377.1 targeting miR-21-5p mediated down expression of SYDE2 correlates with poor prognosis and tumor immune infiltration of ccRCC;Heliyon;2022-10